TCRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

1.94M

+191.73%

-0.276

-4.83%

2.00M

-7.88%

-0.203

-21.8%

1.50M

-51.24%

-0.207

-26.19%

Estimates Revision

The market is revising Upward the revenue expectations for TScan Therapeutics, Inc. (TCRX) for FY2025, with the revenue forecasts being adjusted by 7.79% over the past three months. During the same period, the stock price has changed by -45.25%.

Revenue Estimates for FY2025

Revise Upward

+7.79%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.33%

In Past 3 Month

Stock Price

Go Down

-45.25%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast TCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TCRX is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

3.00

Averages

5.50

High

7.00

Current: 0.000

Low

3.00

Averages

5.50

High

7.00

Morgan Stanley

Maxwell Skor

Overweight -> Equal Weight

downgrade

2025-11-13

Reason

Morgan Stanley

Maxwell Skor

Price Target

2025-11-13

downgrade

Overweight -> Equal Weight

Reason

Morgan Stanley analyst Maxwell Skor downgraded TScan Therapeutics to Equal Weight from Overweight. The firm's new base case price target is now $1-$5 vs. $7-$13 prior. After the company's recent strategic prioritization update, the firm plans to remain on the sidelines until there is greater visibility on near-term catalysts, the analyst tells investors in a research note. This change reflects that the pivotal TSC-101 study is now expected to initiate in Q2 of FY26 vs. prior forecast of the second half of FY25, the firm added.

BTIG

Justin Zelin

Buy -> Neutral

downgrade

2025-11-04

Reason

BTIG

Justin Zelin

Price Target

2025-11-04

downgrade

Buy -> Neutral

Reason

BTIG analyst Justin Zelin downgraded TScan Therapeutics to Neutral from Buy without a price target following the company's decision to prioritize its hematologic malignancy program and pause on enrollment in the solid tumor TCR-T study. BTIG now assumes a late-2029 approval for TSC-101. It cites the delay in an expected TSC-101 launch and removal of the solid-tumor program, coupled with limited near-term share catalysts, for the downgrade.

Needham

Buy

downgrade

$9 -> $6

2025-11-03

Reason

Needham

Price Target

$9 -> $6

2025-11-03

downgrade

Buy

Reason

Needham lowered the firm's price target on TScan Therapeutics to $6 from $9 and keeps a Buy rating on the shares. TScan is consolidating its efforts on lead heme program TSC-101, with an ASH abstract suggesting some loss of activity with TSC-101 compared to data from last year, the analyst tells investors in a research note. Despite these and other recent challenges, the firm continues to view TSC-101 as an important potential solution for rapid relapse in patients receiving transplant.

Needham

Gil Blum

Strong Buy

Reiterates

2025-04-08

Reason

Needham

Gil Blum

Price Target

2025-04-08

Reiterates

Strong Buy

Reason

Morgan Stanley

Maxwell Skor

Buy

Initiates

$10

2025-03-14

Reason

Morgan Stanley

Maxwell Skor

Price Target

$10

2025-03-14

Initiates

Buy

Reason

Morgan Stanley analyst Maxwell Skor assumed coverage of TScan Therapeutics with an Overweight rating and $10 price target. Recent Phase 1 ALLOHA data showed product candidates TSC-100 and TSC-101 outperformed the control arm with 8% of patients relapsing versus 33% in the control arm, notes the analyst, who is focused on additional data from the ALLOHA trial expected by year-end and safety/response data from the multiplex solid tumor program in the second half of 2025.

Barclays

Peter Lawson

Buy

Maintains

$14 → $3

2025-03-07

Reason

Barclays

Peter Lawson

Price Target

$14 → $3

2025-03-07

Maintains

Buy

Reason

Barclays lowered the firm's price target on TScan Therapeutics to $3 from $14 and keeps an Overweight rating on the shares post the Q4 report. The firm says that given the pullback in the stock, it "derisked the model" post the earnings print, focusing the model on transplant and head-neck with "conservative penetration." The analyst still sees upside in the shares.

Valuation Metrics

The current forward P/E ratio for TScan Therapeutics Inc (TCRX.O) is -1.13, compared to its 5-year average forward P/E of -2.48. For a more detailed relative valuation and DCF analysis to assess TScan Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.48

Current PE

-1.13

Overvalued PE

-0.71

Undervalued PE

-4.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.48

Current EV/EBITDA

0.23

Overvalued EV/EBITDA

1.03

Undervalued EV/EBITDA

-1.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

18.85

Current PS

8.46

Overvalued PS

37.73

Undervalued PS

-0.04

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 12447.81% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TCRX News & Events

Events Timeline

No data

News

9.0

2025-12-19PRnewswire

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

9.0

2025-12-19Newsfilter

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

9.0

2025-12-06Globenewswire

TScan Reports 100% Relapse-Free Survival in AML Patients Treated with TSC-101 at Two-Year Follow-Up

People Also Watch

Frequently Asked Questions

What is TScan Therapeutics Inc (TCRX) stock price today?

The current price of TCRX is 1.21 USD — it has increased 2.54 % in the last trading day.

What is TScan Therapeutics Inc (TCRX)'s business?

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

What is the price predicton of TCRX Stock?

What is TScan Therapeutics Inc (TCRX)'s revenue for the last quarter?

TScan Therapeutics Inc revenue for the last quarter amounts to 2.51M USD, increased 139.37 % YoY.

What is TScan Therapeutics Inc (TCRX)'s earnings per share (EPS) for the last quarter?

TScan Therapeutics Inc. EPS for the last quarter amounts to -0.28 USD, increased 12.00 % YoY.

What changes have occurred in the market's expectations for TScan Therapeutics Inc (TCRX)'s fundamentals?

How many employees does TScan Therapeutics Inc (TCRX). have?

TScan Therapeutics Inc (TCRX) has 194 emplpoyees as of January 10 2026.

What is TScan Therapeutics Inc (TCRX) market cap?

Today TCRX has the market capitalization of 68.67M USD.